Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ and an infrared spectrum comprising at least one peak selected from at about 3322 cm −1 and at about 2886 cm −1 .
2. The pharmaceutical composition of claim 1 where the crystalline solid form A consists of greater than 95% by weight (−)-halofenate and less than 5% by weight of other non-solvent compounds.
3. The pharmaceutical composition of claim 1 where the composition is a solid oral composition.
4. The pharmaceutical composition of claim 3 where the composition is a tablet or capsule.
5. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ and a Raman spectrum comprising at least one peak selected from at about 3087 cm −1 and at about 1663 cm −1 .
6. The pharmaceutical composition of claim 5 where the crystalline solid form A consists of greater than 95% by weight (−)-halofenate and less than 5% by weight of other non-solvent compounds.
7. The pharmaceutical composition of claim 5 where the composition is a solid oral composition.
8. The pharmaceutical composition of claim 7 where the composition is a tablet or capsule.
9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ, an infrared spectrum comprising at least one peak selected from at about 3322 cm −1 and at about 2886 cm −1 , and a Raman spectrum comprising at least one peak selected from at about 3087 cm −1 and at about 1663 cm −1 .
10. The pharmaceutical composition of claim 9 where the crystalline solid form A consists of greater than 95% by weight (−)-halofenate and less than 5% by weight of other non-solvent compounds.
11. The pharmaceutical composition of claim 9 where the composition is a solid oral composition.
12. The pharmaceutical composition of claim 11 where the composition is a tablet or capsule.
13. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8° 2θ, about 22.0° 2θ, and about 29.3° 2θ; and an infrared spectrum comprising peaks at about 3322 cm −1 and about 2886 cm −1 .
14. The pharmaceutical composition of claim 13 where the crystalline solid form A consists of greater than 95% by weight (−)-halofenate and less than 5% by weight of other non-solvent compounds.
15. The pharmaceutical composition of claim 13 where the composition is a solid oral composition.
16. The pharmaceutical composition of claim 15 where the composition is a tablet or capsule.
17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8° 2θ, about 22.0° 2θ, and about 29.3° 2θ; and a Raman spectrum comprising peaks at about 3087 cm −1 and about 1663 cm −1 .
18. The pharmaceutical composition of claim 17 where the crystalline solid form A consists of greater than 95% by weight (−)-halofenate and less than 5% by weight of other non-solvent compounds.
19. The pharmaceutical composition of claim 17 where the composition is a solid oral composition.
20. The pharmaceutical composition of claim 19 where the composition is a tablet or capsule.